NIAID encourages applications focused on detection, diagnostics, treatment, and vaccines. Below are areas of interests from the Division of Microbiology and Infectious Diseases (DMID). The subject matter expert is available to answer questions and advise on the application process.
If you do not see your microbiology- or infectious-disease-related topic here, the application may not be prioritized but will still be reviewed. Please contact Barbara Mulach or Natalia Kruchinin if you have any questions about your application and don’t see an appropriate subject matter expert below.
Identify and qualify infectious disease-related biomarkers, including
Barbara MulachOffice of Scientific Coordination and Program Operations
Development of more sensitive and accurate methods of direct detection of Borrelia burgdorferi for the purpose of diagnosing Lyme disease patients
Diagnostic approaches that contain one or more of the following are also encouraged: substantial and significant advances over conventional antibody-based approaches, methods that take into account host response, ability to detect and differentiate multiple strains of Borrelia burgdorferi, and ability to discriminate between active and previous infection.
Vaccines for NIAID Category A, B, and C priority pathogens including influenza, Ebola, Marburg, arenavirus, and other viral encephalitides.
Vaccine development for tuberculosis, STIs, hepatitis B and C, and malaria and other high-impact global parasitic diseases
Vaccine enhancement and formulation technologies with the goal of providing protection against multiple infectious disease agents, providing accelerated immune responses (more rapid schedules or reduced number of immunizations), increasing ease of administration (i.e., self-administration), and increasing product stability to minimize cold chain requirements
Therapeutics for NIAID Category A, B, and C priority pathogens including smallpox, viral hemorrhagic fevers, viral encephalitides, botulinum neurotoxins, and influenza
Therapeutics for tuberculosis, hepatitis B and C, and malaria and other high-impact global parasitic diseases
Therapeutics exhibiting broad-spectrum activity against microbial pathogens
Therapeutic enhancement and formulation technologies with the goal of improving drug development timeframes, productivity, efficacy, specificity, safety, stability, and delivery
Development of simple, rapid, field-deployable, sensitive, and specific point-of-care in vitro diagnostics for
Development of next generation sequencing and genomic technologies for new diagnostic strategies for infectious diseases including molecular signatures developed from studies on human microbiome and pathogen-host interactions
Vaccines, therapeutics, and diagnostics for emerging and re-emerging influenza viruses such as 2009 H1N1 influenza
back to top
Last Updated May 01, 2014
Last Reviewed May 01, 2014